On Monday, the Swiss pharmaceutical giant Novartis (NVS) announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has upheld the validity of the patent for the Entresto (sacubitril/valsartan) combination in the United States. The company stated that it intends to rigorously enforce this combination patent, which benefits from pediatric exclusivity until it expires in July 2025.
Novartis emphasized its commitment to defending and safeguarding its key intellectual property and regulatory rights associated with Entresto. The company also pointed out that there are currently no generic versions of Entresto available in the United States.
The material has been provided by InstaForex Company - www.instaforex.com
Novartis emphasized its commitment to defending and safeguarding its key intellectual property and regulatory rights associated with Entresto. The company also pointed out that there are currently no generic versions of Entresto available in the United States.
The material has been provided by InstaForex Company - www.instaforex.com